Karuna Therapeutics, Inc. Stock News

Clinical-stage biotech, Karuna Therapeutics <> is trading sharply lower on Thursday after the company withdrew its timeline for a key data readout for a late-stage trial citing…

According to an SEC filing, Karuna Therapeutics Inc (NASDAQ: KRTX) is withdrawing its prior guidance for the timing of topline data for its Phase 3 EMERGENT-3 trial evaluating KarXT in schizophrenia

Karuna Therapeutics press release (KRTX): Q4 GAAP EPS of -$0.94.Revenue of $36.96M.

Let's take a deeper dive into Karuna Therapeutics Inc. ( KRTX , Financial), which was one of the potential takeover targets I discussed last week.

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy

GlaxoSmithKline PLC ( GSK , Financial), Pfizer Inc. ( PFE , Financial) and Johnson & Johnson ( JNJ , Financial) should all know about mid-year if the shots they're developing for a common and potentia

In the premium service, we had over a 3x gain in the stock after a Phase 2 trial data to treat acute psychosis in known schizophrenia. Data from the first Phase 3 trial in this indication is expected

A tough 2021 has small-cap stocks positioned for a potentially fruitful 2022. Analysts are most bullish on these 12 picks in the new year.

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy

Parametric Portfolio Associates LLC lessened its position in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX) by 2.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,665 shares of the companys stock after selling 139 shares during the quarter. Parametric Portfolio Associates LLCs []

Karuna Therapeutics, Inc. (NASDAQ:KRTX) has earned an average recommendation of Buy from the fourteen analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and thirteen have given a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on []

Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX) have received a consensus recommendation of Buy from the fourteen analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and thirteen have issued a buy recommendation on the company. The average 1-year price target among analysts that have []

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Director Atul Pande sold 2,500 shares of the companys stock in a transaction dated Wednesday, December 1st. The stock was sold at an average price of $127.73, for a total value of $319,325.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Atul Pande []